Immune-Mediated Therapies for Liver Cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Prognostic and clinicopathological significance of PD-1 expression in hepatocellular carcinoma: a meta-analysis.The Journal of international medical research · 2020
   Pooled it
2. Cost-effectiveness analysis of Tislelizumab vs Sorafenib as the first-line treatment of unresectable hepatocellular carcinoma.PloS one · 2024
   Trial
3. Comprehensive Analysis of Factors Affecting Clinical Response and Short-Term Survival to Drug-Eluting Bead Transarterial Chemoembolization for Treatment in Patients With Liver Cancer.Technology in cancer research & treatment · 2018
   Trial
4. [ERI3 expression is elevated in hepatocellular carcinoma and correlates with poor patient prognosis].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026
   Article
5. Elevated FOXA1 Expression Indicates Poor Prognosis in Liver Cancer due to Its Effects on Cell Proliferation and Metastasis.Disease markers · 2022
   Article
6. A Panel of E2F Target Gene Signature Predicting the Prognosis of Hepatocellular Carcinoma.Frontiers in genetics · 2022
   Article
7. Study on the Application of Doxorubicin-Loaded Magnetic Nanodrugs in Targeted Therapy of Liver Cancer.Applied bionics and biomechanics · 2022
   Article
8. Cell-Based Regeneration and Treatment of Liver Diseases.International journal of molecular sciences · 2021
   Review
9. Specific MiRNAs in naïve T cells associated with Hepatitis C Virus-induced Hepatocellular Carcinoma.Journal of Cancer · 2021
   Article
10. Development of GPC3 and EGFR-dual-targeting chimeric antigen receptor-T cells for adoptive T cell therapy.American journal of translational research · 2021
    Article
11. Humanized mouse model: a review on preclinical applications for cancer immunotherapy.American journal of cancer research · 2020
    Review
12. One Single Site Clinical Study: To Evaluate the Safety and Efficacy of Immunotherapy With Autologous Dendritic Cells, Cytokine-Induced Killer Cells in Primary Hepatocellular Carcinoma Patients.Frontiers in oncology · 2020
    Article
13. Fluid shear stress induces cell migration and invasion via activating autophagy in HepG2 cells.Cell adhesion & migration · 2019
    Article
14. The landscape of novel and complementary targets for immunotherapy: an analysis of gene expression in the tumor microenvironment.Oncotarget · 2019
    Article
15. Development of a new patient-derived xenograft humanised mouse model to study human-specific tumour microenvironment and immunotherapy.Gut · 2018
    Article
16. The Limitations of Standard Clinicopathologic Features to Accurately Risk-Stratify Prognosis after Resection of Intrahepatic Cholangiocarcinoma.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2018
    Article
17. Nanoparticles for the treatment of liver fibrosis.International journal of nanomedicine · 2017
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as